The Effect of Sarpogrelate and High Dose Statin on the Reduction of Coronary Spasm
- Registration Number
- NCT01674686
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
The aim of the study was to to evaluate the effect of sarpogrelate, a selective serotonin receptor antagonist, and high dose statin on the reduction of coronary spasm in the patients with variant angina.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- Clinical history of chest pain compatible with variant angina; morning chest pain aggravated by cold exposure.
- Angiographically proven coronary spasm; TIMI flow < 3 by spontaneous coronary spasm or intracoronary ergonovine spasm provocation test.
Exclusion Criteria
- Cardiac arrest by coronary spasm
- Left main coronary spasm
- Significant fixed coronary artery stenosis; Diameter stenosis > 70% in the major epicardial artery by coronary angiography
- Left ventricular ejection fraction < 30%
- Coagulation disorders or bleeding tendency (Platelet count < 50k, PT INR > 2.0)
- Significant liver disease (AST or ALT > 100 U/ml)
- Renal failure (S-Cr > 2.0 mg/dl)
- hypersensitivity for statin
- Pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Arm && Interventions
Group Intervention Description A Sarpogrelate Sarpogrelate versus placebo B Atorvastatin Atorvastatin 80mg versus no statin or simvastatin 20 mg if LDL \> 130 mg/dl
- Primary Outcome Measures
Name Time Method Ergonovine provocation test 12months later 1 year later
- Secondary Outcome Measures
Name Time Method C-reactive protein lever 12months later 1 year
Trial Locations
- Locations (1)
Hyoen-Cheol Gwon, MD,PhD
🇰🇷Seoul, Korea, Republic of